Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
CONCLUSION: Our findings suggest that optimizing FA dosing to avoid very high rescue doses may improve treatment outcomes in PCNSL patients receiving HDMTX. Further prospective studies are warranted to validate these findings.PMID:38008594 | DOI:10.1016/j.clml.2023.10.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 26, 2023 Category: Cancer & Oncology Authors: Arnon Haran Noa Gross Even-Zohar Michal Haran Eyal Lebel Shlomzion Aumann Adir Shaulov Moshe Gatt Boaz Nachmias Source Type: research
Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
CONCLUSION: Our findings suggest that optimizing FA dosing to avoid very high rescue doses may improve treatment outcomes in PCNSL patients receiving HDMTX. Further prospective studies are warranted to validate these findings.PMID:38008594 | DOI:10.1016/j.clml.2023.10.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 26, 2023 Category: Cancer & Oncology Authors: Arnon Haran Noa Gross Even-Zohar Michal Haran Eyal Lebel Shlomzion Aumann Adir Shaulov Moshe Gatt Boaz Nachmias Source Type: research
SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies
Clin Lymphoma Myeloma Leuk. 2023 Oct 21:S2152-2650(23)02150-X. doi: 10.1016/j.clml.2023.10.006. Online ahead of print.ABSTRACTThe discovery of Venetoclax (VEN) has transformed the therapeutic landscape of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). However, the response is heterogeneous with 10% to 50% of newly diagnosed AML patients not responding to hypomethylating agent (HMA) and VEN. Furthermore, up to 40% of responding patients relapse shortly. This review discusses the mechanism of action of Venetoclax and the major mechanisms of inherent and acquired resistance to VEN. VEN is highly specific...
Source: Clinical Lymphoma and Myeloma - November 25, 2023 Category: Cancer & Oncology Authors: Mark Forsberg Marina Konopleva Source Type: research
Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy
CONCLUSION: Though there is no consensus on optimal treatment indications for RT in LS-DLBCL, these data suggest certain subgroups may have benefit when RT is added to front-line chemotherapy.PMID:38000981 | DOI:10.1016/j.clml.2023.09.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 24, 2023 Category: Cancer & Oncology Authors: Daniel A Ermann Victoria A Vardell Harsh Shah Lindsey Fitzgerald Randa Tao David K Gaffney Deborah M Stephens Boyu Hu Source Type: research
Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy
CONCLUSION: Though there is no consensus on optimal treatment indications for RT in LS-DLBCL, these data suggest certain subgroups may have benefit when RT is added to front-line chemotherapy.PMID:38000981 | DOI:10.1016/j.clml.2023.09.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 24, 2023 Category: Cancer & Oncology Authors: Daniel A Ermann Victoria A Vardell Harsh Shah Lindsey Fitzgerald Randa Tao David K Gaffney Deborah M Stephens Boyu Hu Source Type: research
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)
CONCLUSION: Median OS with both HMAs remained significantly shorter than in the AZA-001 clinical trial, highlighting how patient outcomes vary between clinical and real-world settings. Further research is required to understand why these disparities exist.PMID:37996264 | DOI:10.1016/j.clml.2023.10.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Amer M Zeidan Elizabeth S Mearns Carmen D Ng Anuj Shah Neil Lamarre Archibong Yellow-Duke Neda Alrawashdh Baiyu Yang Wei-Han Cheng Cat N Bui Anders Svensson Source Type: research
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
CONCLUSION: This study supports ixazomib-based therapy as an effective and tolerable treatment in the real-world. Outcomes were favorable in patients with 1 or ≥ 2 prior lines of therapy who were not lenalidomide- or PI-refractory.PMID:37996265 | DOI:10.1016/j.clml.2023.10.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Heinz Ludwig Karthik Ramasamy Mar ía-Victoria Mateos Bhuvan Kishore Varga Gergely Miriam Ladicka Alessandra Ori Lucia Simoni Nawal Bent-Ennakhil Dawn Marie Stull Fran çois Gavini Evangelos Terpos Roman H ájek Source Type: research
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)
CONCLUSION: Median OS with both HMAs remained significantly shorter than in the AZA-001 clinical trial, highlighting how patient outcomes vary between clinical and real-world settings. Further research is required to understand why these disparities exist.PMID:37996264 | DOI:10.1016/j.clml.2023.10.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Amer M Zeidan Elizabeth S Mearns Carmen D Ng Anuj Shah Neil Lamarre Archibong Yellow-Duke Neda Alrawashdh Baiyu Yang Wei-Han Cheng Cat N Bui Anders Svensson Source Type: research
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
CONCLUSION: This study supports ixazomib-based therapy as an effective and tolerable treatment in the real-world. Outcomes were favorable in patients with 1 or ≥ 2 prior lines of therapy who were not lenalidomide- or PI-refractory.PMID:37996265 | DOI:10.1016/j.clml.2023.10.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Heinz Ludwig Karthik Ramasamy Mar ía-Victoria Mateos Bhuvan Kishore Varga Gergely Miriam Ladicka Alessandra Ori Lucia Simoni Nawal Bent-Ennakhil Dawn Marie Stull Fran çois Gavini Evangelos Terpos Roman H ájek Source Type: research
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research
Secondary hypogammaglobulinemia in adults-A large retrospective cohort study
CONCLUSION: SHG was associated with more than one etiological factor and a high frequency of infections. IgG-RT indication was irregular yet still effective. It is relevant to consider IgG levels screening, monitoring and accurate indication of IgG-RT.PMID:37980212 | DOI:10.1016/j.medcli.2023.10.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 18, 2023 Category: Cancer & Oncology Authors: Ernestina Angarola Ver ónica Andrea Peuchot Fernando Warley Diana In és Liberatore Source Type: research
Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis
CONCLUSION: CV toxicity was consistent with clinical trials and other real-world registries. Older age, hypercholesterolemia and a SCORE risk >2% were significantly associated with higher risk of AOEs. Controlling CV risk factors and reducing doses at optimal time points may help to optimize ponatinib use in daily practice.PMID:37973457 | DOI:10.1016/j.clml.2023.10.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 16, 2023 Category: Cancer & Oncology Authors: Mar ía José Mela Osorio Beatriz Moiraghi Mar ía Victoria Osycka Miguel A Pavlovsky Ana In és Varela Georgina Emilia Bendek Del Prete Mar ía Fernanda Tosin Mariel Ana P érez Mar ía Elisa Riva Roxana Ram írez Berrios Isolda Fern ández Federico Sack Source Type: research
